(Q33443571)

English

MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

prostate cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

David J. Bearss

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Christopher Riley

object named as

Christopher Riley

4

0 references

author name string

Wenqing Qi

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Larry S Cooke

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Amy Stejskal

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kimiko Della Croce

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jose W Saldanha

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Daruka Mahadevan

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

11 May 2009

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

142

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

copyright license

Creative Commons Attribution 2.0 Generic

11 May 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

Targeting HER proteins in cancer therapy and the role of the non-target HER3.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

Inhibition of Akt pathways in the treatment of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

Diagnosis of prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

A novel substrate mimetic inhibitor of PKB/Akt inhibits prostate cancer tumor growth in mice by blocking the PKB pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

Therapeutic options in advanced prostate cancer: present and future

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

Cancer statistics, 2007

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

Early effects of pharmacological androgen deprivation in human prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

Management of high risk metastatic prostate cancer: defining risk at the time of initial treatment failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

Conditional Akt activation promotes androgen-independent progression of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

Advances in the treatment of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3'-kinase/Akt pathway and Bcl-2 family proteins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

Mechanisms underlying the development of androgen-independent prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

Akt-regulated pathways in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

Signal transduction in prostate cancer progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

ErbB receptors: possible therapeutic targets in prostate cancer?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

Smart drugs: tyrosine kinase inhibitors in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

Cell signaling by receptor tyrosine kinases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

A tyrosine kinase profile of prostate carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

Stimulatory effects of the protein tyrosine phosphatase inhibitor, pervanadate, on T-cell activation events.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

LNCaP model of human prostatic carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

21 June 2018

Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-142

21 January 2018

Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-142

21 January 2018

Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-142

21 January 2018

Reduction of 14-3-3 proteins correlates with increased sensitivity to killing of human lung cancer cells by ionizing radiation

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-142

21 January 2018

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-142

21 January 2018

Zanthoxyli Fructus induces growth arrest and apoptosis of LNCaP human prostate cancer cells in vitro and in vivo in association with blockade of the AKT and AR signal pathways.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

31 October 2018

PI3K-Akt signaling is involved in the regulation of p21(WAF/CIP) expression and androgen-independent growth in prostate cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

31 October 2018

Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2685437

31 October 2018

Expression and Nuclear Localization of ErbB3 in Prostate Cancer

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-142

21 January 2018

Erlotinib or capecitabine with gemcitabine in pancreatic cancer?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19432987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EXpression of ErbB proteins in human prostate

1 reference

https://pubmed.ncbi.nlm.nih.gov/19432987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER3 and mutant EGFR meet MET

1 reference

https://pubmed.ncbi.nlm.nih.gov/19432987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gene expression correlates of clinical prostate cancer behavior

1 reference

https://pubmed.ncbi.nlm.nih.gov/19432987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ErbB kinases and NDF signaling in human prostate cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19432987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tyrosine kinases as targets for cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19432987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-9-142

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33443571&oldid=2249123580"